Head-to-head · WeighScore
HumeCare+ vs yourEra
By GLP-1 ScorecardUpdated
Score comparison
yourEra has the higher recorded score — 83.8/100 to 58.6/100.
yourEra grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Compounded semaglutide and tirzepatide injections advertised at $89/$129 monthly for new patients, with a named medical practice and three possible pharmacies; confirm the continuing price because homepage and terms differ.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | HumeCare+ | yourEra |
|---|---|---|
| WeighScore | 58.6/100 | 83.8/100 |
| Grade | C | B |
| Site position | #328 | #7 |
| Semaglutide | GLP-1 page advertises $199 billed monthly and a first four-week supply; homepage labels a three-month plan from $199/month. Confirm the selected total and formulation additions. | $89/mo (new-patient offer; confirm refill terms) |
| Tirzepatide | Named on the public GLP-1 menu, but no separate current public prescription price confirmed; obtain the selected medication and renewal quote. | $129/mo (new-patient offer; confirm refill terms) |
| Coverage | Homepage/footer exclude Louisiana and Mississippi; GLP-1 FAQ also excludes Alabama. Confirm current treatment-specific eligibility, especially Alabama. | 50-state clinician network; treatment availability varies by state |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #328 · C
Strengths
- Advertises a Hume Pod and app within the homepage package; other selected plans may differ
- Current terms describe a single subscription including consultation and prescribed fulfilled medication, with added charges requiring disclosure and consent
- Publicly identifies MDI Medical Group PC as the clinical network and provides a clinician directory; assignment and current individual licenses still need confirmation
- Terms allow cancellation before renewal through the account Subscription section or support email
What to consider
- Homepage three-month pricing and the GLP-1 page’s monthly billing description do not establish one selected initial charge or renewal calendar
- Ninety-day, 180-day and six-month results-refund advertisements do not have matching claim rules in the current terms; customer-canceled prepaid periods are not prorated
- Muscle-preservation, side-effect and outcome advantages are merchant claims, not established benefits of the prescribed compound or tracking device
- No exact prescribing dose, vial quantity, usable supply or patient-lab price is confirmed by the public package
- The dispensing pharmacy and physical compounder are not named in the reviewed terms or shipping policy
- Alabama availability differs between the GLP-1 FAQ and site footer; general eligibility does not guarantee every preparation
- Next-day advertising differs from published clinical-review, pharmacy-processing and carrier estimates; a free included device does not create a separate device cash refund
Site position #7 · B
Strengths
- Public new-patient month-to-month prices; advertised same price across doses while active
- Evaluation, medication, injection supplies, dose management and shipping advertised together
- Terms name Thryv Telehealth by Lavin, P.C. and three potential dispensing pharmacies
- Free requested live visit; policy promises full refund if canceled before dispatch
What to consider
- Compounded formulations are not FDA-approved branded products
- Homepage price-continuation promise and terms allowing future refill price changes need reconciliation
- Optimum coaching, nutrition, at-home labs and wearables are coming soon, with no confirmed price or launch date
- Assessment usually asynchronous; prescription issuance triggers billing, and treatment availability varies by state
Featured provider
yourEra
yourEra scores 83.8/100 (B). Compounded semaglutide and tirzepatide injections advertised at $89/$129 monthly for new patients, with a named medical practice and three possible pharmacies; confirm the continuing price because homepage and terms differ.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.